MAIA Biotechnology, Inc. MAIA

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

MAIA Biotechnology, Inc. (MAIA, the Company, we, or us) is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Ateganosine (THIO, 6-thio-dG or 6-thio-2

‘-deoxyguanosine), our lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting

and immunogenicity. In July 2022, the first patient was administered with ateganosine in our Phase 2 human trial (THIO-101) in Australia.

In December 2022, regulatory authorities in three European countries, Hungary, Poland, and Bulgaria, approved the implementation of THIO-101,

Last close 1.15 2026-10-23
Market cap $69.9M 2026-06-30 share count
52-week range 0.87 - 3.19

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.70

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Revenue —$0$0$0——
R&D $453.7K$10.0M$11.1M$8.9M$3.5M—
SG&A $9.7M$6.9M$9.1M$6.1M$4.3M—
Total operating expenses $24.3M$17.0M$20.2M$16.2M$7.8M—
Operating income -$24.3M-$17.0M-$20.2M-$16.2M-$7.8M—
Interest expense —$57$6.9K$7.0K$827.5K—
Pre-tax income -$22.4M-$23.3M-$19.8M-$15.8M-$12.6M—
Income tax $2.0K$2.0K————
Net income -$22.4M-$23.3M-$19.8M-$15.8M-$12.6M—
EPS, basic -0.70-1.05-1.49-1.75-2.37—
EPS, diluted -0.70-1.05-1.49-1.75-2.37—
Shares, diluted (wtd. avg.) 32.1M22.2M13.3M9.3M5.3M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents $0$0$0$11.0M$10.6M$663.5K
Total current assets $9.7M$10.2M$7.6M$11.8M$10.7M—
Total assets $9.7M$10.2M$7.6M$12.0M$11.3M—
Accounts payable $2.0M$1.5M$1.6M$1.2M$960.4K—
Total current liabilities $5.8M$3.8M$4.9M$3.3M$2.1M—
Total liabilities $7.3M$6.5M$7.1M$3.5M$2.1M—
Retained earnings -$109.6M-$87.2M-$64.0M-$44.2M-$28.4M—
Total equity $2.4M$3.6M$477.5K$8.5M$9.2M-$1.6M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Operating cash flow -$18.8M-$15.7M-$13.1M-$12.1M-$4.1M—
Stock-based compensation $2.6M$1.9M$3.1M$2.3M$2.7M—
Financing cash flow $17.9M$18.2M$9.3M$12.5M$14.0M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-012088.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -30M -20M -10M 0 Net income, FY2021: -12.6M Revenue, FY2022: 0 Net income, FY2022: -15.8M Revenue, FY2023: 0 Net income, FY2023: -19.8M Revenue, FY2024: 0 Net income, FY2024: -23.3M Net income, FY2025: -22.4M FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — $0 $0 $0 —
Gross profit — — — — — —
Net income — -$12.6M -$15.8M -$19.8M -$23.3M -$22.4M

Recent filings and events

  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Other event Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Other event Item 8.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Other event Item 8.01
  • Other event Item 8.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%